Clinical Trials Logo

Filter by:
NCT ID: NCT06236464 Recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas

Start date: September 25, 2023
Phase:
Study type: Observational

This is a multicentric, retrospective, and prospective biomarker study.

NCT ID: NCT06236399 Recruiting - Clinical trials for Human Brain and Cognition

An EEG Study on the Rhythmic Nature of Perception and Attention

Start date: November 13, 2023
Phase:
Study type: Observational

The study involved healthy volunteers (n= 200), in a single center, low-risk intervention protocol of a non-profit nature. The objective of the study is to investigate the neural mechanisms of visual perception and attention, with particular reference to neural oscillations, in the general population through electroencephalogram (EEG) recording and the administration of simple visual tasks on a PC. The study presented is not associated with risks, as EEG is a non-invasive technique for which there are no known contraindications or adverse reactions.

NCT ID: NCT06236373 Recruiting - Breast Cancer Clinical Trials

The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia

Survivorship
Start date: April 20, 2023
Phase:
Study type: Observational

This qualitative study seeks to explore the unmet needs of individuals who have recently undergone a cancer diagnosis and completed the acute phase of treatment. The primary objective is to utilize the experiences of patients, caregivers, and stakeholders to enhance the aftercare provided to cancer survivors. By delving into patient perceptions regarding unmet needs in cancer aftercare, the study aims to identify areas for redesigning and improving services to minimize these needs and ultimately enhance patient outcomes. Importantly, the investigation incorporates insights from patients, their caregivers, and stakeholders. The research will employ qualitative methods, specifically focus groups and interviews, to gather comprehensive perspectives from individuals in the Ausl IRCCS Reggio Emilia district who have completed treatment for breast, prostate, colorectal, thyroid, and multiple myeloma cancers. Including patients with diverse cancer types is crucial for capturing a broad spectrum of experiences. During data collection, both focus group discussions and interviews will be recorded in audio format and transcribed verbatim. This meticulous approach ensures an accurate representation of participants' voices and experiences. The subsequent analysis will employ a combination of framework and thematic analysis to extract meaningful insights and synthesize the data effectively. The study's ultimate goal is to leverage the findings to optimize aftercare services for cancer survivors within the local context of Ausl IRCCS Reggio Emilia. By incorporating the perspectives of patients, caregivers, and stakeholders, the research aims to contribute valuable insights that can inform the redesign and improvement of aftercare services, ultimately benefitting cancer survivors in the region.

NCT ID: NCT06235268 Recruiting - Clinical trials for Carcinoma, Urothelial

Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Start date: November 23, 2023
Phase:
Study type: Observational [Patient Registry]

Prospective and multicenter Italian registry intended for naïve adult patients affected by locally advanced-metastatic urothelial carcinoma intended for systemic treatment, or for palliative or observation procedures

NCT ID: NCT06235047 Completed - Clinical trials for Classic Hodgkin Lymphoma

Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)

Start date: January 1, 2013
Phase:
Study type: Observational

Study on the use of a polychemotherapy scheme based on liposomal doxorubicin, vinblastine and dacarbazine (MVD) as first line in the therapy of elderly patients affected by classic Hodgkin lymphoma

NCT ID: NCT06234800 Completed - Clinical trials for Implant Complication

Observational Study on Implant Removal

Start date: January 4, 2003
Phase:
Study type: Observational

Reporting of the reason for implant removal in a hospital setting over 20 years. retrospective design.

NCT ID: NCT06234579 Recruiting - NSCLC Stage IV Clinical Trials

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

GALILEO
Start date: July 12, 2021
Phase:
Study type: Observational

The scope of GALILEO project (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) is to explore the feasibility of genomic longitudinal evaluation for ALK+ NSCLC patients in Italian routine practice and provide a detailed overview of resistance mechanisms and clinical outcomes according to current standard treatments.

NCT ID: NCT06234449 Not yet recruiting - Clinical trials for Pelvic Organ Prolapse

The Impact of Long-term Pessary Use on Pelvic Organ Prolapse oìduring Covid-19 Pandemic in Patients Attending Surgery

Start date: July 2024
Phase:
Study type: Observational [Patient Registry]

Patients aged 45 to 80 years with a clinical diagnosis of stage III and IV genital prolapse involving the anterior and/or middle compartments and candidates for surgery will be considered. These will be evaluated to observe whether there is improvement in clinical prolapse with the use of the vaginal pessary during the waiting period for surgery

NCT ID: NCT06233461 Recruiting - Crohn's Disease Clinical Trials

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Start date: March 5, 2024
Phase: Phase 2
Study type: Interventional

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.t

NCT ID: NCT06232707 Withdrawn - Multiple Myeloma Clinical Trials

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

ALUMMINATE
Start date: May 3, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).